Rapid Health allegedly submitted false claims to Medicare for over-the-counter COVID-19 tests that were not provided to Medicare beneficiaries.

Foresight said Roche failed to bring its trade-secret causes of action within the three-year statute of limitations.

NEW YORK — Laboratory-developed tests, FDA actions, the JP Morgan Healthcare Conference, and Roche — perhaps not surprisingly these subjects dominated the attention of 360Dx readers in 2024. Reader ...

Top Five Articles on 360Dx Last Week: Labcorp Asset Acquisition, Roche CE Mark for Mass Spec, More Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for ...

NEW YORK – For clinical labs, 2024 will most likely be remembered as the year the US Food and Drug Administration finally made good on its decades-old promise — or threat, depending on your point of ...

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: Labcorp to Acquire Select Assets of MAWD Pathology Group Roche Nabs CE Mark for New ...

NEW YORK – Diagnostics firm Fujirebio and drugmaker Eisai said Monday that they have entered a memorandum of understanding for research into and use of blood-based biomarkers for neurodegenerative ...